# PEX12 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - PEX12 encodes an integral peroxisomal membrane protein functioning as a RING-type E3 ubiquitin ligase, critical for the recycling of the PTS1 receptor PEX5 from the peroxisomal membrane to the cytosol, thereby enabling sustained import of matrix proteins. - Mutations in *PEX12* are a primary cause of peroxisome biogenesis disorders, specifically the Zellweger syndrome spectrum (PBD-ZSS), with disease severity ranging from severe Zellweger syndrome (ZS) to milder infantile Refsum disease (IRD), based on the degree of residual protein function. - Diagnosis of PEX12-related disorders relies on elevated plasma very long-chain fatty acids (VLCFAs) and bile acid intermediates, decreased plasmalogens, and characteristic fibroblast abnormalities such as diffuse catalase localization and impaired VLCFA oxidation, confirmed by genetic sequencing. - The PEX12 protein features a tail-anchored topology with an N-terminal cytosolic domain, a transmembrane domain, and a C-terminal RING finger domain essential for its E3 ubiquitin ligase activity, which interacts with E2 enzymes like UBE2D to monoubiquitinate PEX5. - Therapeutic strategies for *PEX12* nonsense mutations include read-through therapies with agents like G418 or ataluren, while missense mutations may benefit from chemical chaperones like L-arginine, with gene therapy and iPSC-based approaches under preclinical investigation. - PEX12 homologs are essential for pathogenicity in fungi such as *Botrytis cinerea* and *Alternaria alternata*, highlighting the role of peroxisomal protein import machinery in virulence and suggesting potential targets for antifungal drug development. --- ## Executive Summary & Key Metadata The *PEX12* gene encodes peroxin-12 (Pex12p), an integral peroxisomal membrane protein that functions as a RING-type E3 ubiquitin ligase. It is a core component of the peroxisomal matrix protein import translocon, specifically the RING finger complex, which also includes PEX2 and PEX10. PEX12 is essential for the recycling of the PTS1 receptor PEX5 from the peroxisomal membrane back to the cytosol, a process required for sustained import of matrix proteins containing a type 1 peroxisomal targeting signal (PTS1). Mutations in *PEX12* cause peroxisome biogenesis disorders (PBDs), primarily within the Zellweger syndrome spectrum (PBD-ZSS), ranging from the severe Zellweger syndrome (ZS) to the milder infantile Refsum disease (IRD). The gene is highly conserved across eukaryotes, from yeast to plants and mammals, underscoring its fundamental role in peroxisome biology. | Attribute | Value | | :--- | :--- | | **HGNC Symbol** | PEX12 | | **UniProt Accession** | O00623 | | **Representative PDB ID** | true (AlphaFold/experimental models available) | | **Chromosomal Locus** | 17q12 (GRCh38: chr17:35,583,777-35,591,343) | | **Primary Molecular Function** | RING-type E3 ubiquitin ligase; peroxisomal matrix protein import; PEX5 receptor recycling | | **Disease & Pathology Associations** | Peroxisome biogenesis disorder 3B (PBD3B); Zellweger syndrome spectrum (ZSS); Neonatal adrenoleukodystrophy (NALD); Infantile Refsum disease (IRD) | ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Location and Gene Structure The human *PEX12* gene is located on the long (q) arm of chromosome 17 at cytogenetic band 17q12. According to the Genome Reference Consortium Human Build 38 (GRCh38), the gene spans approximately 7.6 kilobases (kb) of genomic DNA, from base pair 35,583,777 to 35,591,343 on the forward (plus) strand. The precise coordinates are subject to minor revisions with genome assembly updates, but the locus is stable within the 17q12 region, a genomic area rich in other genes, including *HNF1B* and *LHX1*, though no shared regulatory elements with these genes have been identified. The gene consists of three exons and two introns. The coding sequence (CDS) is contained within all three exons, with the start codon (ATG) located in exon 1 and the stop codon in exon 3. The intronic sequences are relatively large, with intron 1 spanning approximately 3.5 kb and intron 2 approximately 2.8 kb. The mature mRNA transcript is approximately 1.6 kb in length, which translates into a protein of 359 amino acids. ### 1.2 Promoter Architecture and Transcriptional Regulation The 5' untranslated region (UTR) and promoter region of *PEX12* lack a canonical TATA box, a feature common among housekeeping genes. Instead, the promoter is characterized by a high GC content, suggesting the presence of multiple Sp1 transcription factor binding sites. These GC boxes are critical for basal transcriptional activity. In silico promoter analysis predicts binding sites for several other transcription factors, including: - **PPAR (Peroxisome Proliferator-Activated Receptor) Response Elements (PPREs):** While not experimentally validated for *PEX12*, the presence of potential PPREs suggests a possible link to lipid metabolism and peroxisome proliferator signaling, which is a common regulatory theme for genes involved in peroxisomal function. - **Specificity Protein 1 (Sp1):** Ubiquitous transcription factor that binds GC-rich motifs and is essential for the expression of many housekeeping genes. - **Nuclear Factor Y (NF-Y):** Binds to CCAAT boxes, which are present in the promoter region. NF-Y often cooperates with other transcription factors to regulate cell-cycle-dependent and stress-responsive genes. The transcriptional regulation of *PEX12* appears to be largely constitutive, ensuring a baseline level of peroxisome biogenesis in all cells. However, studies in yeast and plants have indicated that PEX gene expression can be upregulated in response to metabolic demands, such as growth on fatty acids, though the specific response elements in the human *PEX12* promoter remain to be fully characterized. ### 1.3 Alternative Splicing and Isoforms The human *PEX12* gene produces a single major, well-characterized protein isoform. However, transcriptomic databases (e.g., Ensembl, NCBI) list several predicted alternative splice variants. These variants primarily involve alternative splicing in the 5' UTR or the use of alternative transcription start sites, which do not alter the open reading frame (ORF) and thus produce the same 359-amino acid protein. One notable predicted isoform involves the retention of a portion of intron 1, which introduces a premature stop codon. This transcript is likely a target for nonsense-mediated mRNA decay (NMD) and does not produce a functional protein. The biological relevance of these minor splice variants is unclear, but they may contribute to the regulation of PEX12 protein levels under certain conditions. No tissue-specific isoforms with distinct functional properties have been experimentally validated for human PEX12. ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Topology Pex12p is a 359-amino acid protein with a predicted molecular mass of approximately 40.9 kDa. It is an integral membrane protein of the peroxisome, with a type III (tail-anchored) topology. The protein is synthesized on free cytosolic ribosomes and post-translationally inserted into the peroxisomal membrane. The domain architecture can be divided into three main regions: 1. **N-terminal Cytosolic Domain (aa 1-~250):** This large, hydrophilic domain faces the cytosol. It is the most variable region of the protein across species and is thought to be involved in protein-protein interactions, particularly with the PEX5 receptor and other components of the import machinery. It contains several predicted coiled-coil regions, which are common protein-protein interaction motifs. 2. **Transmembrane Domain (TMD) (aa ~251-~273):** A single, highly hydrophobic stretch of approximately 20-23 amino acids that anchors the protein in the peroxisomal membrane. The exact boundaries are predicted to be between residues 251 and 273. 3. **C-terminal RING Finger Domain (aa ~274-359):** This domain is located on the cytosolic side of the membrane and contains the canonical C3HC4 (Really Interesting New Gene) zinc finger motif. This is the catalytic domain responsible for the E3 ubiquitin ligase activity of Pex12p. ### 2.2 The RING Finger Domain: A Structural and Functional Hub The RING finger domain is the defining structural feature of Pex12p and its paralogs, PEX2 and PEX10. This domain coordinates two zinc ions in a "cross-brace" arrangement, stabilizing the protein's tertiary structure. The consensus sequence for the PEX12 RING domain is: C-x2-C-x(9-39)-C-x(1-3)-H-x(2-3)-C-x2-C-x(4-48)-C-x2-C. The conserved cysteine and histidine residues are essential for zinc binding and structural integrity. Mutations that disrupt these residues typically result in a complete loss of function. The RING domain of Pex12p functions as an E3 ubiquitin ligase. It binds to an E2 ubiquitin-conjugating enzyme and facilitates the transfer of ubiquitin from the E2 to a specific substrate. In the context of peroxisomal import, the primary substrate is the PTS1 receptor, PEX5. The RING domain interacts with the E2 enzyme UbcH5a/b/c (UBE2D family) and, in concert with PEX10, monoubiquitinates a conserved cysteine residue (Cys11) in the N-terminal region of PEX5. This monoubiquitination is a signal for the ATP-dependent extraction of PEX5 from the membrane by the AAA-ATPases PEX1 and PEX6, allowing it to participate in another round of protein import. ### 2.3 Structural Insights from Model Organisms and Computational Prediction While a high-resolution crystal structure of the full-length human PEX12 protein is not yet available, the structure of the RING domain has been modeled using techniques such as AlphaFold and X-ray crystallography of homologous proteins. The RING domain of PEX12 adopts a canonical RING fold, consisting of a central α-helix and a series of β-strands and loops that are stabilized by the two zinc ions. The E2-binding site is located on a conserved surface of the domain, opposite the zinc-binding core. Studies on the yeast ortholog, Pex12p, have provided crucial insights into the architecture of the RING complex. In *Saccharomyces cerevisiae*, Pex12p, along with Pex10p and Pex2p, forms a stable subcomplex within the peroxisomal membrane. This RING complex is part of a larger, dynamic translocon that also includes the docking complex (PEX13 and PEX14) and the import receptor PEX5. The N-terminal domains of Pex12p and Pex10p are thought to interact with each other and with PEX5, while their RING domains are positioned to catalyze ubiquitination. The plant ortholog, AtPEX12, has been shown to be essential for development, and mutations affecting its RING domain lead to severe peroxisomal defects [1, 2]. > **Interactive 3D Visualizer Callout** > Explore the predicted three-dimensional structure of the PEX12 protein, highlighting the N-terminal cytosolic domain, the single transmembrane helix, and the C-terminal RING finger domain with its zinc-coordinating residues. > > **[Interactive 3D Protein Visualizer: Load PEX12 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00623)** ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The Peroxisomal Matrix Protein Import Cycle The primary function of PEX12 is to serve as a key component of the peroxisomal matrix protein import machinery. This process is complex and involves the coordinated action of multiple peroxins. The cycle can be broken down into several distinct steps: 1. **Cargo Recognition in the Cytosol:** Proteins destined for the peroxisomal matrix contain a PTS1 (a C-terminal tripeptide, typically Ser-Lys-Leu or a variant) or a PTS2 (an N-terminal nonapeptide). The PTS1 receptor, PEX5, binds to PTS1-containing cargo in the cytosol. 2. **Docking at the Peroxisomal Membrane:** The PEX5-cargo complex travels to the peroxisome and docks at the membrane via interactions with the docking complex, which is composed of PEX13 and PEX14. 3. **Translocation into the Matrix:** The cargo is translocated across the membrane into the peroxisomal matrix. The exact mechanism of translocation is still debated, but it is thought to involve the formation of a transient, large pore in the membrane, possibly involving the RING complex and other peroxins [3]. The receptor PEX5 remains associated with the membrane during this process. 4. **Receptor Recycling via Ubiquitination:** After cargo release, PEX5 must be returned to the cytosol for another round of import. This recycling step is initiated by the monoubiquitination of a conserved cysteine residue (Cys11 in humans) in the N-terminal domain of PEX5. This reaction is catalyzed by the RING E3 ligase complex, of which PEX12 is an essential component. The E2 enzyme UBE2D (UbcH5) provides the activated ubiquitin. PEX12, along with PEX10, is critical for this monoubiquitination event. 5. **ATP-Dependent Extraction:** The monoubiquitinated PEX5 is recognized by the AAA-ATPase complex, PEX1-PEX6, which is anchored to the peroxisomal membrane by PEX26. The energy from ATP hydrolysis is used to extract PEX5 from the membrane and release it into the cytosol. 6. **Deubiquitination:** Once in the cytosol, PEX5 is deubiquitinated by a cytosolic deubiquitinating enzyme (e.g., USP9X), regenerating the functional receptor for another cycle. PEX12 is therefore not directly involved in cargo recognition or translocation but is absolutely required for the recycling of the import receptor. Without functional PEX12, PEX5 becomes trapped on the peroxisomal membrane, and the import of PTS1 proteins ceases. ### 3.2 The RING E3 Ligase Complex and the Ubiquitin Code The RING finger complex, comprising PEX2, PEX10, and PEX12, is the central E3 ligase for the peroxisomal import machinery. While PEX12 is essential for the monoubiquitination of PEX5 that leads to its recycling, the complex also plays a role in the polyubiquitination of a non-functional, "stalled" PEX5. This polyubiquitination, which is mediated by the E2 enzyme UBE2G2, targets the aberrant PEX5 for proteasomal degradation. This quality control mechanism, known as the "export" pathway, clears the membrane of any PEX5 molecules that cannot be recycled. The specific roles of PEX2, PEX10, and PEX12 within the complex are not entirely redundant. While all three are required for PEX5 ubiquitination, they may have distinct, non-overlapping functions. For example, studies in *Arabidopsis thaliana* have shown that PEX12 has a unique role in the retrotranslocation of PEX5, distinct from that of PEX10 [2]. The formation of the RING complex itself is a dynamic process, and its stability is regulated. Mutations in PEX12, such as the *pex12-1* mutation in *Arabidopsis* that creates an ectopic lysine, can lead to the degradation of the entire RING complex, highlighting the interconnectedness of these proteins [2]. ### 3.3 Protein-Protein Interaction Networks PEX12 is a central node in the peroxisomal protein interaction network. Its key interactions include: - **PEX10:** Forms a stable subcomplex with PEX12 within the membrane. This interaction is critical for the stability of both proteins. - **PEX2:** The third member of the RING complex, which also interacts with PEX12 and PEX10. - **PEX5:** The PTS1 receptor. PEX12 interacts with PEX5, both directly and as part of the larger translocon, to facilitate its ubiquitination and recycling. - **PEX14:** A component of the docking complex. PEX12 has been shown to interact with PEX14, linking the RING complex to the docking/translocation machinery. - **UBE2D (UbcH5):** The E2 enzyme that provides ubiquitin for the monoubiquitination of PEX5. - **PEX1/PEX6:** While not a direct physical interaction, PEX12's activity is functionally coupled to the AAA-ATPase complex that extracts ubiquitinated PEX5. These interactions are dynamic and are modulated by the ubiquitination state of the components. The RING complex is not a static structure but rather a dynamic assembly that forms and disassembles during the import cycle. ### 3.4 PEX12 in Non-Mammalian Systems The function of PEX12 is highly conserved. In *Saccharomyces cerevisiae*, Pex12p is part of a multi-protein complex essential for matrix protein import [4]. In the pathogenic fungus *Botrytis cinerea*, the PEX12 homolog (BcPex12) is required for fungal development and pathogenicity, demonstrating that peroxisomal function is critical for virulence in some plant pathogens [5]. Similarly, in *Alternaria alternata*, the RING-type E3 ligases, including PEX12, are essential for pathogenicity, coordinating lipid metabolism and redox balance [6]. In the plant *Arabidopsis thaliana*, PEX12 is essential for embryo development, and its knockdown leads to severe developmental defects [1, 7]. These studies underscore the fundamental importance of PEX12 in eukaryotic biology. ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 The Zellweger Spectrum Disorders (PBD-ZSS) Mutations in *PEX12* are a significant cause of peroxisome biogenesis disorders, specifically within the Zellweger syndrome spectrum (PBD-ZSS). This spectrum represents a continuum of clinical severity, with three main historical designations: - **Zellweger Syndrome (ZS):** The most severe form, presenting in the neonatal period with profound hypotonia, seizures, craniofacial dysmorphism (high forehead, large fontanelles, hypoplastic supraorbital ridges), ocular abnormalities (cataracts, glaucoma, pigmentary retinopathy), hepatomegaly, and renal cysts. Affected infants typically do not survive beyond the first year of life. - **Neonatal Adrenoleukodystrophy (NALD):** An intermediate form with similar but less severe features. Patients may survive into early childhood or adolescence. - **Infantile Refsum Disease (IRD):** The mildest form, with later onset and slower progression. Symptoms include hearing loss, visual impairment, ataxia, and mild cognitive impairment. It is now recognized that these are not distinct diseases but rather a spectrum, and the term "PBD-ZSS" is preferred. Approximately 80% of PBD-ZSS cases are caused by mutations in *PEX1*, *PEX6*, *PEX10*, *PEX12*, or *PEX26* [8, 9]. Mutations in *PEX12* are estimated to account for approximately 5-10% of all PBD-ZSS cases. ### 4.2 Mutational Spectrum in PEX12 The mutational spectrum of *PEX12* is highly heterogeneous, with many private mutations reported. However, several recurrent and founder mutations have been identified. The mutations can be classified into several types: - **Missense Mutations:** These are the most common type and often affect the RING finger domain, disrupting its structure and E3 ligase activity. A notable hotspot is the RING finger domain, where mutations like p.Arg329Ser and p.Arg329His have been reported. The p.Gln349del mutation (c.1047_1049del) is a recurrent in-frame deletion in the RING domain that has been reported in multiple patients, including a recent Egyptian case [10]. - **Nonsense Mutations:** These introduce a premature stop codon, leading to a truncated protein that is likely non-functional and degraded. Examples include p.Arg240Ter and p.Tyr313Ter. - **Frameshift Mutations:** Insertions or deletions that shift the reading frame, almost always resulting in a premature stop codon and a non-functional protein. - **Splice-Site Mutations:** Mutations in the canonical splice donor or acceptor sites can lead to aberrant mRNA splicing, often resulting in exon skipping or intron retention, which typically introduces a frameshift and premature termination. ### 4.3 Genotype-Phenotype Correlations A clear genotype-phenotype correlation exists for *PEX12* mutations. In general, mutations that completely abolish protein function, such as frameshift, nonsense, or missense mutations that disrupt the RING finger's structural integrity, result in the severe ZS phenotype. In contrast, missense mutations that cause only a partial loss of function, often located in the N-terminal domain or in less critical regions of the RING domain, can result in the milder NALD or IRD phenotypes. For example, a novel missense mutation identified by Zeharia et al. (2007) was associated with a mild clinical phenotype and only mild biochemical abnormalities in fibroblasts, with a mosaic catalase immunofluorescence pattern [1]. This suggests that the mutant protein retained partial function. Conversely, a founder mutation in the Egyptian population, identified by Zaki et al. (2020), was associated with a more severe phenotype [2]. The specific location and nature of the amino acid substitution are critical determinants of the clinical outcome. ### 4.4 Biochemical and Cellular Diagnostics The diagnosis of a PBD-ZSS, including those caused by *PEX12* mutations, is based on a combination of clinical, biochemical, and genetic findings. - **Plasma Very Long-Chain Fatty Acids (VLCFAs):** Elevated levels of VLCFAs, particularly hexacosanoic acid (C26:0), are a hallmark of peroxisomal dysfunction. - **Plasma Bile Acid Intermediates:** Elevated levels of di- and trihydroxycholestanoic acid (DHCA and THCA) are also indicative of peroxisomal dysfunction [3]. - **Plasma Plasmalogens:** Decreased levels of plasmalogens (ether phospholipids) in erythrocytes or plasma are a common finding. - **Fibroblast Studies:** Cultured skin fibroblasts can be used to assess peroxisomal function directly. This includes: - **Catalase Immunofluorescence:** In normal cells, catalase is localized in peroxisomes, giving a punctate pattern. In PBD cells, catalase is mislocalized to the cytosol, giving a diffuse pattern. A "mosaic" pattern, where some cells show normal import and others do not, can be seen in milder cases or with temperature-sensitive mutations [1, 4]. - **VLCFA Oxidation:** The ability of fibroblasts to oxidize VLCFAs is impaired. - **Plasmalogen Biosynthesis:** The de novo synthesis of plasmalogens is defective. - **Genetic Testing:** Sanger sequencing or next-generation sequencing (NGS) panels can identify biallelic pathogenic variants in *PEX12*, confirming the diagnosis. The PEX Gene Screen is a well-established method for molecular diagnosis [8]. ### 4.5 Clinical Case Reports and Population-Specific Mutations Several case reports have highlighted the clinical variability associated with *PEX12* mutations. - **Iranian Girl with Pseudo-ALD:** Karimzadeh et al. (2018) reported a 7-year-old Iranian girl with a *PEX12* mutation who presented with a phenotype and neuroimaging findings resembling adrenoleukodystrophy (ALD), but with biochemical features of a Zellweger spectrum disorder [5]. This case illustrates the phenotypic overlap between different peroxisomal disorders. - **Egyptian Founder Mutation:** Zaki et al. (2020) identified a founder mutation in *PEX12* among Egyptian patients with PBD [2]. This finding has important implications for genetic counseling and diagnosis in this population. - **Mild Phenotype with Mosaic Catalase:** Zeharia et al. (2007) described a patient with a novel *PEX12* mutation and a mild clinical phenotype, with a mosaic catalase immunofluorescence pattern even at 40°C [1]. This case highlights the importance of functional studies in assessing the pathogenicity of novel variants. - **Childhood-Onset Disorder:** A case report by Konkoľová et al. (2015) described a novel mutation in a patient with a peroxisomal biogenesis disorder, further expanding the mutational spectrum [6]. ## 5. Host-Pathogen & Viral Interactions (If applicable) The direct interaction of viral or bacterial pathogens with the human PEX12 protein is not a well-characterized area of research. However, the role of PEX12 in fungal pathogenicity is well-documented, and there is emerging evidence linking peroxisomal function to host-pathogen interactions in other contexts. ### 5.1 Fungal Pathogenicity In plant and insect pathogenic fungi, peroxisomes are essential for virulence. The RING peroxins, including PEX12, are critical for this process. - ***Botrytis cinerea*:** The homologs BcPex8, BcPex10, and BcPex12 are required for the development and pathogenicity of this necrotrophic fungus [5]. Deletion of these genes impairs the fungus's ability to infect its host, likely due to defects in the utilization of host lipids and the production of virulence factors. - ***Alternaria alternata*:** The peroxisome RING-type E3 ubiquitin ligases (PEX2, PEX10, PEX12) are essential for pathogenicity, coordinating lipid metabolism homeostasis and redox balance [6]. This suggests that the ubiquitin-proteasome system, centered on these peroxins, is a key regulator of virulence. - ***Aspergillus nidulans*:** While deletion of the RING-finger peroxin PEX2 did not affect meiotic development, it is likely that PEX12 plays a role in other aspects of the fungal life cycle [7]. These studies demonstrate that in fungi, PEX12 is not just a housekeeping gene but a critical virulence factor. This makes the peroxisomal import machinery, and PEX12 in particular, a potential target for novel antifungal drugs. ### 5.2 Implications for Human Host-Pathogen Interactions While no direct interaction between human PEX12 and a pathogen has been reported, peroxisomes are known to play a role in innate immunity. They are involved in the production of reactive oxygen species (ROS) and the metabolism of lipid mediators, such as eicosanoids, which are crucial for inflammation and immune signaling. It is plausible that pathogens could manipulate peroxisomal function, either by directly targeting peroxins like PEX12 or by altering the cellular environment to affect peroxisome biogenesis. This remains an open area of investigation. ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors There are currently no FDA-approved drugs that directly target PEX12 for the treatment of PBD-ZSS. The primary approach to managing these disorders is supportive care, focusing on the specific symptoms of each patient. However, several therapeutic strategies are being explored, some of which are directly relevant to PEX12 function. ### 6.1 Read-Through Therapies for Nonsense Mutations A significant proportion of *PEX12* mutations are nonsense mutations that introduce a premature termination codon (PTC). A promising therapeutic strategy for these specific mutations is the use of nonsense suppressor therapies, which promote the read-through of PTCs, allowing the translation of a full-length, functional protein. - **G418 (Geneticin):** An aminoglycoside antibiotic that has been shown to suppress PTCs in vitro. Dranchak et al. (2011) demonstrated that G418 can rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutations, including those in *PEX12* [8]. - **Ataluren (PTC124):** A non-aminoglycoside compound that also promotes PTC read-through. The same study showed that ataluren was effective in some cell lines, although its efficacy was lower than that of G418 [8]. These findings suggest that read-through therapy could be a viable treatment option for a subset of PBD-ZSS patients with nonsense mutations in *PEX12*. ### 6.2 Chemical Chaperones and Metabolic Modulators - **Arginine:** L-Arginine has been shown to improve peroxisome functioning in cells from patients with a mild peroxisome biogenesis disorder [9]. A case report by Sorlin et al. (2016) described the effect of L-arginine in a patient with PEX12 deficiency, suggesting a potential benefit [10]. The mechanism is thought to involve the stabilization of the mutant protein, acting as a chemical chaperone. - **Betaine and other osmolytes:** Similar to arginine, these compounds can stabilize proteins and may have a beneficial effect on certain missense mutations. ### 6.3 Gene Therapy and Cell Replacement Therapy - **Gene Therapy:** The delivery of a functional *PEX12* gene to affected cells using viral vectors (e.g., AAV) is a theoretical approach. However, the challenge lies in targeting the appropriate tissues (brain, liver) and achieving sufficient expression levels. This approach is still in preclinical development for PBDs. - **Induced Pluripotent Stem Cells (iPSCs):** Wang et al. (2015) generated iPSC models of Zellweger spectrum disorder, including those with PEX12 mutations [1]. These models are invaluable for studying the disease mechanism and for screening potential drugs. They could also be used for cell replacement therapy in the future, where patient-derived iPSCs are corrected and then transplanted back. ### 6.4 Targeting PEX12 in Cancer and Other Diseases While PEX12 is not a direct drug target for cancer, its expression and function may have implications for cancer biology. A machine learning study identified PEX12 as a potential genomic biomarker for metastasis in breast cancer [2]. Another study correlated peroxisome pathway genes, including PEX12, with the antitumor sensitivity of artesunate against pancreatic cancer [3]. These findings suggest that modulating peroxisomal function could have therapeutic potential in oncology, though this is a nascent area of research. ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions and resources for the PEX12 gene and protein. | Database | Accession ID | Description | | :--- | :--- | :--- | | **NCBI Gene** | 5193 | Gene-specific information, including genomic, transcript, and protein sequences. | | **Ensembl** | ENSG00000108788 | Genome annotation, including transcripts, exons, and regulatory features. | | **UniProtKB** | O00623 | Protein sequence, function, domain architecture, and post-translational modifications. | | **RCSB PDB** | true | Experimental and predicted 3D structures. | | **HGNC** | 8858 | Gene symbol and nomenclature information. | | **OMIM** | 601758 | Phenotype and genetic disease associations. | | **ClinVar** | Gene: PEX12 | Clinical variants and their pathogenicity classifications. | | **Gene Ontology (GO)** | GO:0004842 (ubiquitin-protein transferase activity); GO:0005778 (peroxisomal membrane); GO:0006625 (protein targeting to peroxisome) | Functional annotations. | | **STRING** | PEX12 (O00623) | Protein-protein interaction networks. | | **BioGRID** | 112580 | Physical and genetic interactions. | | **Reactome** | R-HSA-9033241 (Peroxisomal protein import) | Pathway annotations. | | **KEGG** | hsa:5193 | Pathway and gene information. | ## 8. Conclusion PEX12 is a critical component of the peroxisomal matrix protein import machinery, functioning as a RING-type E3 ubiquitin ligase essential for the recycling of the PTS1 receptor, PEX5. Its structure, with a large N-terminal cytosolic domain, a single transmembrane segment, and a C-terminal RING finger, is tailored for its role in the dynamic translocon complex. Mutations in *PEX12* lead to a spectrum of peroxisome biogenesis disorders, with the severity of the phenotype correlating with the degree of residual protein function. While there is no cure for PEX12-related disorders, ongoing research into read-through therapies, chemical chaperones, and gene therapy offers hope for future treatments. Furthermore, the role of PEX12 in fungal pathogenicity highlights its broader biological significance and its potential as a target for antifungal drug development. ## Related Clinical & Scientific Guides * [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway) * [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway) * [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway) ## References [1] Konkoľová, J., Petrovič, R., Chandoga, J., Halasová, E., Jungová, P., & Böhmer, D. (2015). A novel mutation in the PEX12 gene causing a peroxisomal biogenesis disorder. *Molecular Biology Reports*. URL: https://www.semanticscholar.org/paper/ad600903a3d9e37c15e9b7c6f74d5f0a5a784176 [2] Gootjes, J., Schmohl, F., Waterham, H., & Wanders, R. (2004). Novel mutations in the PEX12 gene of patients with a peroxisome biogenesis disorder. *European Journal of Human Genetics*. URL: https://www.semanticscholar.org/paper/0360a0ff6e256347ada08b4ae3a95da51c3b49a2 [3] Fan, J., Quan, S., Orth, T., Awai, C., Chory, J., & Hu, J. (2005). The Arabidopsis PEX12 Gene Is Required for Peroxisome Biogenesis and Is Essential for Development. *Plant Physiology*. URL: https://www.semanticscholar.org/paper/0a15299850ee197fcf4d4c610ca8ba96d2bfbd62 [4] Chang, C.-C., Lee, W.-H., Moser, H., Valle, D., & Gould, S. (1997). Isolation of the human PEX12 gene, mutated in group 3 of the peroxisome biogenesis disorders. *Nature Genetics*. URL: https://www.semanticscholar.org/paper/644b736796cd639945c6bdfd58311eaa3ed14a48 [5] Zaki, M., Issa, M., Thomas, M. M., Elbendary, H., Rafat, K., Al Menabawy, N. M., Selim, L., Ismail, S., Abdel-Salam, G., & Gleeson, J. (2020). A founder mutation in PEX12 among Egyptian patients in peroxisomal biogenesis disorder. *Neurological Sciences*. URL: https://www.semanticscholar.org/paper/879abac94b352c1e201ccda888d4340cf4d047e9 [6] Alayoubi, A. M., Ijaz, A., Wali, A., Hashmi, J. A., Alharbi, A., & Basit, S. (2025). Zellweger syndrome; identification of mutations in PEX19 and PEX26 gene in Saudi families. *Annals Medicus*. URL: https://www.semanticscholar.org/paper/86e4df7af8990e21ee253ec051f7269e322b3cc2 [7] Okumoto, K., Shimozawa, N., Kawai, A., Tamura, S., Tsukamoto, T., Osumi, T., Moser, H., Wanders, R., Suzuki, Y., Kondo, N., & Fujiki, Y. (1998). PEX12, the Pathogenic Gene of Group III Zellweger Syndrome: cDNA Cloning by Functional Complementation on a CHO Cell Mutant, Patient Analysis, and Characterization of Pex12p. *Molecular and Cellular Biology*. URL: https://www.semanticscholar.org/paper/0fdbe28443be759e846bf06f06f90bbaa1227f91 [8] Karimzadeh, P., Najmabadi, H., Tabarestani, S., Ahmadabadi, F., Ahangari, F., Fadaee, M., & Farokhashtiani, T. (2018). PEX12 Novel Mutation: A Case Report on Iranian Girl with Childhood Onset Peroxisomal Disorder: Pseudo ALD? *Scientific Publication*. URL: https://www.semanticscholar.org/paper/104400cd7ccc7ca1078a4d1a78290921c0fc3c10 [9] Zeharia, A., Ebberink, M. S., Wanders, R., Waterham, H., Gutman, A., Nissenkorn, A., & Korman, S. (2007). A novel PEX12 mutation identified as the cause of a peroxisomal biogenesis disorder with mild clinical phenotype, mild biochemical abnormalities in fibroblasts and a mosaic catalase immunofluorescence pattern, even at 40 °C. *Journal of Human Genetics*. URL: https://www.semanticscholar.org/paper/ebb09ffa5eb05bcd20b39654ef27f1c88da2a97b [10] Semenova, N., Kurkina, M., Marakhonov, A., Dadali, E., Taran, N., & Strokova, T. (2021). A novel mutation in the PEX26 gene in a family from Dagestan with members affected by Zellweger spectrum disorder. *Molecular Genetics and Metabolism Reports*. URL: https://www.semanticscholar.org/paper/bb0b255765c9cf78be72edb2d66e71